Accelerate Net Income Per E B T from 2010 to 2024

AXDX Stock  USD 1.70  0.13  8.28%   
Accelerate Diagnostics Net Income Per E B T yearly trend continues to be fairly stable with very little volatility. Net Income Per E B T will likely drop to 0.74 in 2024. During the period from 2010 to 2024, Accelerate Diagnostics Net Income Per E B T regression line of annual values had r-squared of  0 and arithmetic mean of  0.97. View All Fundamentals
 
Net Income Per E B T  
First Reported
2010-12-31
Previous Quarter
1.01398763
Current Value
0.74
Quarterly Volatility
0.07624939
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Accelerate Diagnostics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Accelerate Diagnostics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 3.4 M, Interest Expense of 8.1 M or Selling General Administrative of 35.9 M, as well as many indicators such as Price To Sales Ratio of 3.85, Dividend Yield of 2.0E-4 or Days Sales Outstanding of 75.39. Accelerate financial statements analysis is a perfect complement when working with Accelerate Diagnostics Valuation or Volatility modules.
  
Check out the analysis of Accelerate Diagnostics Correlation against competitors.
For more information on how to buy Accelerate Stock please use our How to Invest in Accelerate Diagnostics guide.

Latest Accelerate Diagnostics' Net Income Per E B T Growth Pattern

Below is the plot of the Net Income Per E B T of Accelerate Diagnostics over the last few years. It is Accelerate Diagnostics' Net Income Per E B T historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Accelerate Diagnostics' overall financial position and show how it may be relating to other accounts over time.
Net Income Per E B T10 Years Trend
Very volatile
   Net Income Per E B T   
       Timeline  

Accelerate Net Income Per E B T Regression Statistics

Arithmetic Mean0.97
Geometric Mean0.96
Coefficient Of Variation7.88
Mean Deviation0.05
Median1.00
Standard Deviation0.08
Sample Variance0.01
Range0.274
R-Value(0.06)
Mean Square Error0.01
R-Squared0
Significance0.83
Slope(0)
Total Sum of Squares0.08

Accelerate Net Income Per E B T History

2024 0.74
2023 1.01
2017 0.99
2015 1.0
2011 0.98
2010 0.83

About Accelerate Diagnostics Financial Statements

Accelerate Diagnostics investors use historical fundamental indicators, such as Accelerate Diagnostics' Net Income Per E B T, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Accelerate Diagnostics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Net Income Per E B T 1.01  0.74 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Accelerate Stock Analysis

When running Accelerate Diagnostics' price analysis, check to measure Accelerate Diagnostics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Accelerate Diagnostics is operating at the current time. Most of Accelerate Diagnostics' value examination focuses on studying past and present price action to predict the probability of Accelerate Diagnostics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Accelerate Diagnostics' price. Additionally, you may evaluate how the addition of Accelerate Diagnostics to your portfolios can decrease your overall portfolio volatility.